MXPA00001611A - 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives - Google Patents

Abstract

2(4-Aryl or Heteroaryl-piperazin-1-ylmethyl)-1H-Indole derivatives of formula (I) wherein a, T, V, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined above, their pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds or their salts interacting with the dopamin D4 receptor.

Description

DERIVATIVES OF 2 - (4-ARIL OR HETEROARIL-PIPERAZIN-1-ILMETIÜ-1H-INDOL The present invention relates to 2- (4-aryl or heteroaryl-piperazin-1-methylmethyl) -1H-indole derivatives having central dopaminergic activity. Such compounds are useful in the treatment of disorders of the Central Nervous System (CNS). This invention also relates to a method of using said compounds in the treatment of the above disorders in mammals, especially in humans and the useful pharmaceutical compositions thereof. It is generally known that dopamine receptors appear to be important for many functions in the animal body. For example, the altered functions of these receptors are involved in the genesis of psychosis, drug addiction, compulsive disorders, bipolar disorders, emesis vision, sleep disorders, eating disorders, learning disorders, memory disorders, of sexual behavior, of the regulation of immunological responses and of blood pressure. Since these receptors control a large number of pharmacological events, all of which are not currently known, there is a possibility that compounds that act preferentially on the dopamine D4 receptor may exert a wide range of therapeutic effects in humans. The 2- (4-aryl or heteroaryl-piperazin-1-ylmethyl) -1H-indole derivatives of the present invention, including the forms of the tautomers, enantiomers and acceptable acid addition salts, are D4 receptor agonists. of dopamine that act centrally and, thus, are useful as stimulators of cognition and for the treatment of CNS diseases, such as Parkinson's disease, Alzeihmer's disease and learning and memory anomalies. Another feature of this invention provides the use of the combinations of compounds of the present invention together with the dopamine D1, D2, D3 or D5 receptor agonists, such as the L-dopa agonists and the D2 agonists, in the treatment of CNS diseases, such as Parkinson's disease, Alzeihmer's disease, attention deficit disorder and learning and memory abnormalities.

BRIEF DESCRIPTION OF THE INVENTION The present invention relates to a compound of formula or the pharmaceutically acceptable salt thereof, wherein the dotted line represents an optional double bond; a is 0 or 1, wherein when a is O, X can form an optional double bond with the carbon adjacent to V; V is CHR10, wherein R10 is hydrogen or alkyl (Ci-Cß); T is nitrogen or CH; X is nitrogen or CR11, wherein R11 is hydrogen, alkyl (d-Cß), alkoxy (C? -C6), hydroxy or cyano; Y and Z are each independently nitrogen or CR12, wherein R12 is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C -? - C6) alkoxy or (C-i-C?) Alkyl; R1 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or (C -? - C6) alkyl; R2, R6, R7, R8, and R9 are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C-i-C) alkoxy, and (C6C6) alkyl; R3 and R4 are each independently hydrogen or alkyl (C6C6); and R5 is hydrogen, (C -? - C6) alkoxy, trifluoromethyl, cyano, (d-C6) alkyl or R13CO, wherein R13 is amino, alkyl amino, ((C? -C6)) 2 amino alkyl, alkyl (CrC6), aryl (C6-C-? O); or when a is 1, R1 and R10 can be linked with the carbons to which they are attached to form a compound of formula in which the dashed lines represent optional bonds; T, X, Y, Z, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined above; b is O or 1; and A and B are each independently CH, CH2, oxygen, sulfur, NH or nitrogen; with the proviso that when X is nitrogen, the optional double bond between X and V does not exist; with the proviso that when b is 0, the optional double bond between A and B does not exist; and with the proviso that when b is 1, A and B can not be any of them oxygen or sulfur. The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic radicals or combinations thereof. The term "alkoxy", as used herein, includes O-alkyl groups, wherein "alkyl" is as defined above. The term "treating", as used herein, refers to reversing, alleviating, inhibiting the progress of the disorder or condition, or preventing the disorders to which the term is applied, or one or more symptoms of such disorders. or conditions. The term "treatment", as used herein, refers to the act of treating, being "treated" as defined immediately above. The term "disorders of the dopamine system", as referred to herein, refers to the disorders, the treatment of which may be effected or facilitated, by altering (i.e., increasing or decreasing) the neuro-transmission mediated by dopamine. The compounds according to the present invention, being linked to the dopamine receptor subtypes, especially the D4 dopamine receptor, within the organism, are suitable for use in the treatment of disorders of the dopamine system. The compound of formula I can have chiral centers and, therefore, exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof. Preferred compounds of formula I include those in which X is nitrogen. Other preferred compounds of formula I include those in which Y and Z are each CR12, wherein R12 is hydrogen or fluoro. Other preferred compounds of formula I include those in which R 2 is hydrogen, fluoro or chloro.

Other preferred compounds of formula I include those in which R3, R4 and R5 are hydrogen. Other preferred compounds of formula I include those in which R7 is fluoro or chloro. Other preferred compounds of formula I include those in which R9 is fluoro, chloro, bromo, or alkoxy. More preferred compounds of formula I include those in which X is nitrogen; Y and Z are each of them CR13, wherein R13 is hydrogen or fluoro; R2 is hydrogen, fluoro or chloro; R3, R4 and R5 are hydrogen; R7 is fluoro or chloro; and R9 is fluoro, chloro, bromo or alkoxy. Preferred specific compounds of formula I include the following: 2- [4- (3-trifluoromethyl-phenyl) -piperazin-1-ylmethyl] -1H-indole; 5-fluoro-2- [4- (3-trifluoromethyl-phenyl) -piperazin-1-ylmethyl] -1H-indole; 5-fluoro-2- [4- (4-fluoro-phenyl) -piperazin-1-ylmethyl] -1H-indole; 5-fluoro-2- [4-pyridin-2-yl-p-piperazin-1-methyl] -1 H-indole; 2- [4- (6-Chloro-pip-r-dazin-3-yl) -piperazin-1-yl-methyl] -5-fluoro-1 H-indole; 5-fluoro-2- (4- [5'-fluoro] pyridin-2-yl-piperazin-1-methyl] -1 H-indole; 2- (4-pyridin-2-yl-piperazin-1-ylmethyl) -1 H-azaindole; 5-fluoro-2- (4-pyridin-2-yl-piperazin-1-ylmethyl) -1 H-azaindole; and 2- [4- (4-fluoro-phenyl) -piperazin-1-ylmethyl] -1 H-azaindole; The present invention also relates to a method for treating disorders of the dopamine system, including psychotic disorders (affective psychosis, schizophrenia and schizoaffective disorders), movement disorders (extrapyramidal side effects of neuroleptic agents, neuroleptic malignant syndrome, dyskinesia late, Gilles De La Tourette syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical substance abuse, chemical dependency, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension ), eye disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a selective dopamine D4 receptor compound according to formula I, or a pharmaceutically acceptable salt thereof, which is effective for the tratment of said disorder. The present invention also relates to a method for treating disorders of the dopamine system, which includes psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects of neuroleptic agents, neuroleptic malignant syndrome, late dyskinesia, Gilles De La Tourette syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical substance abuse, chemical dependency, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), eye disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a selective compound of the dopamine D4 receptor according to formula I, or a pharmaceutically acceptable salt thereof, together with a or more agonists of the r D1, D2, D3 or D5 eceptors of dopamine which is effective in treating said disorder. The present invention also relates to a pharmaceutical composition for treating disorders of the dopamine system, which includes psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects of neuroleptic agents, neuroleptic malignant syndrome , late dyskinesia, Gilles De La Tourette syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical substance abuse, chemical dependency, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), eye disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a selective compound of the dopamine D4 receptor according to formula I, or a pharmaceutically acceptable salt thereof, which is effective to treat said disorder. The present invention also relates to a pharmaceutical composition for treating disorders of the dopamine system, which includes psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects of neuroleptic agents, malignant syndrome neuroleptic, late dyskinesia, Gilles De La Tourette syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical substance abuse, chemical dependency, substance abuse, vascular and cardiovascular disorders (heart failure) congestive and hypertension), eye disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a selective dopamine D4 receptor compound according to formula I, or a pharmaceutically acceptable salt thereof, together with one or more Dopamine D1, D2, D3 or D5 receptor agonists which is effective in treating said disorder.

DETAILED DESCRIPTION OF THE INVENTION The following reaction schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated, a, T, V, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8 and R9 in the reaction schemes and the following description, are as defined previously.

SCHEME 1 SCHEME 2 SAW V In reaction 1 of scheme 1, the compounds of formula III and IV are coupled to form the corresponding compound of formula I, first treating III with O-, N-dimethylhydroxylamine hydrochloride, dicyclohexylcarbodiimide and a base, such as triethylamine, in a polar aprotic solvent, such as methylene chloride. The hydroxyamide intermediate thus formed is reduced, using a reducing agent, such as lithium aluminum hydride, in a polar aprotic solvent, such as tetrahydrofuran. The reductive amination of the aldehyde intermediate thus formed is carried out by reaction of the aldehyde with the compound of formula IV in the presence of sodium triacetoxyborohydride and a polar aprotic solvent, such as dichloroethane. The reaction mixture is stirred, in an inert atmosphere, at room temperature for a period of time between about 40 hours to about 56 hours, preferably about 48 hours. In reaction 1 of scheme 2, the compounds of formula VI, wherein L is a leaving group, such as chlorine, bromine, methoxy or any activated ester derivative, such as the para-nitro phenyl ester, the hydroxy benzotriazole ester, the ester of N-hydroxysuccinamide or hydroxy, and IV are coupled to form the corresponding methanone compound of formula III by reaction of VI and IV in the presence of diisopropylethylamine, carbodiimide or a dehydrating agent and polar aprotic solvent, such as chloride of methylene, or in the form of mixtures containing, if desired, combinations of organic solvents or water, such as combinations of cyclic and acyclic mono- and dialkylamides, (C-? - C4) alcohols, halogenated solvents or acyclic alkyl ethers and cyclics at temperatures ranging from about 0 ° C to about 150 ° C, preferably at about 0 ° C or the boiling point of the same solvent mixture. The addition of an acid acceptor, such as alkyl carbonate, a tertiary amine or a similar reagent, could be useful. In reaction 2 of scheme 2, the methanone compound of formula V is converted into the corresponding compound of formula I, wherein R 3 and R 4 are hydrogen, by reduction of V with a reducing agent, such as lithium aluminum hydride or a borane derivative, in the presence of a polar aprotic solvent, such as tetrahydrofuran, for a period of time between about 10 hours to about 14 hours, preferably about 12 hours. In each of the above reactions, the pressure is not critical. Pressures in the range of about 50.65 kPa to 101.3 kPa are appropriate, with ambient pressure (generally about 101.3 kPa) being preferred for convenience. In addition, for those reactions, where the preferred temperature varies with the particular compounds that react, no preferred temperature is cited. By said reactions, the preferred temperatures for the particular reagents can be determined by controlling the reaction using thin layer chromatography. The novel compounds of formula I and the pharmaceutically acceptable salts thereof (herein "the therapeutic compounds of this invention") are useful as dopaminergic agents, i.e., possess the ability to alter dopamine-mediated neurotransmission in mammals, including humans. Accordingly, they are capable of acting as therapeutic agents in the treatment or prevention can be effected or can be facilitated by an increase or decrease in the neurotransmission mediated by dopamine.

The compounds of formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desired in practice to initially isolate a compound of formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter into the free base compound, by treatment with an alkaline reagent and subsequently converting this latter free base into a pharmaceutically acceptable acid addition salt. The acid addition salts of the basic compounds of this invention are readily prepared by treating the basic compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in an appropriate organic solvent, such as methanol or ethanol. By carefully evaporating the solvent, the desired solid salt is easily obtained. The desired acid salt can also be precipitated in a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution. The therapeutic compounds of this invention can be administered orally, transdermally, (for example, by the use of a patch), parenterally or topically. Oral administration is preferred. In general, it is more desirable to administer these compounds in dosages ranging from about 0.1 mg to about 1000 mg per day, or 1 mg to 1000 mg per day in some cases, although variations may occur depending on the weight and disorder of the person to be treated, and the particular route of administration chosen. In some cases, dosage levels below the lower limit of the range mentioned above may be the most appropriate, while in other cases higher doses may be employed without causing any harmful side effects, provided that these higher doses are first divided. in several small doses for administration throughout the day. The therapeutic compounds of the invention can be administered alone or in combination with pharmaceutically acceptable carriers or diluents by one of the two aforementioned routes, said administration being possible in single or multiple doses. More especially, the novel therapeutic compounds of this invention can be administered in a wide range of different dosage forms, that is, they can be combined with different pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders. , sprays, creams, ointments, suppositories, gelatins, gels, pastes, lotions, ointments, elixirs, syrups and the like. Such vehicles include, for example, solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents. Also, oral pharmaceutical compositions can be sweetened and / or flavored appropriately. For oral administration, tablets containing various excipients may be used, such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine, together with various disintegrants such as starch (and preferably, corn, potato or tapioca starch). , alginic acid and certain complex silicates, together with binders for granulation, such as polyvinylpyrrolidone, sucrose, gelatin and gum arabic. In addition, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for the manufacture of tablets. Solid compositions of a similar type can also be employed as fillers in gelatin capsules; in this regard, the preferred materials also include lactose or milk sugar, as well as high molecular weight polyethylene glycols. When aqueous suspensions and / or elixirs are desired for oral administration, the active ingredient can be combined with various sweetening or flavoring agents, colorants or dyes, and if desired, also with emulsifying and / or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and various similar combinations of the same. For parenteral administration, solutions of a compound of the present invention may be employed in sesame oil or peanut oil or in aqueous propylene glycol. The aqueous solutions should be appropriately buffered if necessary, the liquid diluent first being isotonic. These aqueous solutions are suitable for intravenous injections. Oily solutions are suitable for intra-articular, intramuscular and subcutaneous injections. The preparation of all these solutions under sterile conditions is easily accomplished by pharmaceutically conventional techniques well known to those skilled in the art. In addition, it is also possible to administer the compounds of the present invention topically when treating inflammatory skin disorders, preferring to do this by creams, jellies, gels, pastes, ointments and the like, in accordance with conventional pharmaceutical practice. The ability of the compounds to bind dopamine receptors of mammals and the relative ability of the compounds of this invention to inhibit the binding of [3 H] -spiperone to the dopamine D receptor subtypes expressed in cell lines were measured clones, using the following procedure.

Binding capacity to the D4 receptor The determination of the binding capacity to the D4 receptor has been described by Van Tol et.al. (Nature, 1991, 350. 610). Cation cell lines expressing the human D4 receptor of dopamine are collected and homogenized (polytron) in a 50 mM Tris: HCL buffer (pH 7.4 at 4 ° C), containing 5 mM EDTA, 1.5 mM calcium chloride (CaCl2) , 5 mM magnesium chloride (MgCl 2), 5 mM potassium chloride (KCl) and 120 mM sodium chloride (NaCl). The homogenates are centrifuged for 10-15 min at 48,000 g and the resulting pellet is suspended in a buffer at a concentration of 150-250 mg / ml. For the saturation experiments, aliquots of 0.75 ml of tissue homogenate are incubated in triplicate with increasing concentrations of [3 H] -spiperone (70.3 Ci / mmol, final concentration 10-3000 pM) for 30-120 minutes at 22 ° C in a total volume of 1 ml. For competitive binding experiments, the assays are started by adding 0.75 ml of membrane and incubated in duplicate with the indicated concentrations of the competitive ligands (10 ~ 14 - 10"3 M) and / or [3H] - spiperone (100 - 300 pM) for 60-120 minutes at 22 ° C. The tests are terminated by rapid filtration through a Brandcell cell harvester and then the filters are checked for the presence of tritium, as described by Sunahara, R. K et.al. (Nature, 1990, 346, 76) For all experiments, the specific binding of [3 H] -spiperone is defined as that inhibited by 1-10 mM (+) - butaclamol. are analyzed by adjusting the non-linear curve of the minimum table The compounds of the examples were analyzed in this test and it was found that all of them had binding affinities (K) for the displacement of the [3 H] -spiperone from less of 2 micromolar.

Modulation by the Human D4 Receptor of the cAMP Formation Chinese hamster ovary (CHO) cells expressing the human dopamine D receptor of Dr. H. Van Tol (Institute Clarke of Psychiatry, Toronto) and were made to grow until confluence in Minimum Essential Alpha Medium (Gibco) supplemented with Fetal Bovine Serum 2. 5% (not heat inactivated), Equine Serum 2.5% (inactivated by heat) and 500 μg / ml Geneticin. The monolayers were disrupted and the cells disintegrated with 5 mM ethylenediaminetetraacetic acid (EDTA) and resuspended in phosphate buffered saline buffer containing 5 mM magnesium chloride, 30 mM hydroxyethylpiperazine-N-ethanesulfonic acid (HEPES), 3-isobutyl -1-methyl-xanthine 300 μM (IBMX, an inhibitor of phosphodiesterase) and dextrose 5.6 mM. Cells (approximately 200,000 / tube) were exposed to 5μM forscolin (an adenylate cyclase activator), forscholine plus test compounds or quinpirole (a D4 receptor agonist) or forscolin plus quinpirole plus antagonist for 11 minutes. In the experiments with antagonists, the cells were exposed to the antagonists 11 minutes before exposure to the agonist. The effect of the test compounds in the absence of the quinpirole agonist was used to determine the agonist activity. The D4 agonists produce an inhibition of cAMP accumulation, which can be reversed by the D4 receptor antagonists. The reaction was terminated with the addition of 6N perchloric acid and the samples were neutralized with 5N potassium hydroxide and 2M Tris buffer. Cyclic AMP levels were measured using commercially available competitive binding equipment (Amersham). The IC50 values were calculated by linear regression analysis of the concentration-response curves. The values K i were calculated using the equation K 1 = Cl 5o / (1+ [agonstasta 7 [EC50 agonist].] (Minneman and Johnson, 1984) The present invention is illustrated by the following examples, but is not limits to the details of them.

EXAMPLE 1 2-r4- (6-Chloro-pyridazin-3-yl) -piperazin-1-methyl-H-5-fluoro-1 H -indole A mixture of 5 g of 5-fluoro-2-indole carboxylic acid is stirred., 2.74 g of O-, N-dimethyl hydroxylamine hydrochloride, 3.89 ml of triethylamine and 5.76 g of dicyclohexylcarbodiimide in 35 ml of methylene chloride, at room temperature until a tan precipitate forms. The solid is removed by filtration, the residue concentrated and purified over SiO 2 (25%) AcOEt in hexane) obtained is 3.6 g (64%) of the N-O-dimethyl-2-indole hydroxyamide. 3.9 N-O-dimethyl-2-indole hydroxylamine is added over a period of 5 minutes to a cold suspension (-40 ° C) of 0.67 of LiAlH4 in 30 ml of tetrahydrofuran. The mixture is stirred for one hour (-40 ° C - >30 ° C), treated with a saturated aqueous solution of sodium sulfate and heated to room temperature. The solvent is removed after the addition of solid sodium sulfate and concentrated until a solid precipitate forms (2.94 g of 5-fluoro-2-indolecarboxyaldehyde). A mixture of 0.96 g of 4- (5-chloro-phenyl) -piperazine, 1.0 g of 5-fluoro, 2-indolecarboxyaldehyde and 1.2 g of sodium triacetoxyborohydride in 50 ml of dichloroethane is stirred under nitrogen at room temperature for 48 hours. The solvent is removed and the residue is partitioned between 100 ml of AcOEt and 20 ml of NaOH (1 N). The organic layer is washed with water (2 x 20 ml) and brine (1 x 10 ml) and concentrated. The residue is purified on SiO2 (eluent: 5% methanol in methylene chloride) to give 1.02 g of a creamy colored solid having a p.f of 204-205 ° C).

EXAMPLE 2 5 -Fluoro- (1H-indol-2-yl-4- (3-trifluoromethyl-phenyl) -piperazin-1-in-methanone A mixture of 1.0 mmol of 5-fluoro-2-indole-carboxylic acid chloride and 230 mg of meta-trifluoromethylphenylpiperazine and 129 mg of diisopropylethylamine in 10 ml of methylene chloride is maintained at room temperature for 12 hours. Water is added, the organic layers are separated, washed with water, dried over sodium sulfate and concentrated to give 296 mg of the title compound. P.F .: 198 ° C.

EXAMPLE 3 5-Fluoro-2- hydrochloride | _- (3-trifluoromethyl-phenyl) -piperazin-1-methyl-methyl-1H-indole A solution of 275 mg of 5-fluoro-1 H-indol-2-yl) - [4- (3-trifluoromethyl-phenyl] -piperazin-1-yl] metatone in 5 ml of anhydrous tetrahydrofuran it is kept in an inert gas atmosphere and treated at room temperature with 2.11 ml of a 1M lithium aluminum hydride solution in tetrahydrofuran. After 12 hours, the mixture is treated with 78 μl of a 15% sodium hydroxide solution and again with 234 μl of water. After adding the magnesium sulfate, the organic layer is separated and concentrated giving a yellow oil (240 mg). This oil is dissolved in ether and treated with an ethereal solution of hydrochloric acid until a precipitate is formed. The precipitate is collected and dried under vacuum. The compounds of the titles of Examples 4 were prepared by a procedure analogous to that described in Example 1-3.

EXAMPLE 4 2-f4- (3-Trifluoromethyl-phenyl) -piperazin-1-ylmethin-1 H -indole-5-ol PF: 188-190 ° C; HRSMS 375.15.

EXAMPLE 5 2-r4- (3-Trifluoromethyl-phenyl) -piperazin-1-methylmethin-1 H-indole PF: 192-194 ° C; HRSMS 359.15.

EXAMPLE 6 (1 H -indole-2-ylH4- (2-n-tro-phenyl) -piperazin-1-yl-methanone MP: 186-189 ° C.

EXAMPLE 7 (5-Fluoro-1H-indol-2-yl) -r4- (2-nitro-phenyl) -piperazin-1-in-methanone PF: 184-188 ° C.

EXAMPLE 8 (5-Fluoro-1H-indol-2-yl) -r4- (3-trifluoromethyl-phenyl) -piperazin-1-in-methanone PF: 198 ° C.

EXAMPLE 9 3-r4- (1H-indol-2-methylmethyl) -piperazin-1-in-benzo Tdl isothiazole PF: 150-152 ° C; MRSMS 348.12.

EXAMPLE 10 5-Fluoro-2-r4- (3-trifluoromethyl-phenyl) -piperazin-1-ylmetin-1 H-indole PF: 196-197 ° C; HRSMS 377,148.

EXAMPLE 11 2- (4-Naphthalen-1-yl-piperazin-1-ylmethyl) -1 H-indole PF: 238-239 ° C; HRSMS 341.19.

EXAMPLE 12 2-r4- (N-8-phenyl) -piperazin-1-l-methyl-1-H-indole PF: 210-211 ° C; HRSMS 336.16.

EXAMPLE 13 -Fluoro-2-r4- (2-nitro-phenyl) -piperazin-1-ylmethip-1 H-indole PF: 236 ° C; HRSM 354.14.

EXAMPLE 14 (5-Fluoro-2- (4-naphthalen-1-yl-piperazin-1-ylmethyl) -1 H-indole PF: 249-250 ° C; HRSMS 359.18.

EXAMPLE 15 5-Fluoro-2- (4-pyridin-2-yl-p-piperazin-1-ylmethyl) -1 H-indole PF: 242 ° C; HRSMS 310.15.

EXAMPLE 16 5-Fluoro-2-r-4- (4-fluoro-phenyl) -piperazin-1-ylmethyl-1 H-indole PF: EXAMPLE 17 5-Fluoro-2- (4-pyrimidin-2-yl-piperazin-1-ylmethyl) -1 H-indole PF: 199 ° C; HRSMS 311.16.

EXAMPLE 18 (5-Fluoro-1H-indol-2-yl) - (4-pyridin-2-yl-piperazin-1-yl) -metanone PF: 214-218 ° C.

EXAMPLE 19 2- (4-Pyridin-2-yl-piperazin-1-ylmethyl) -1 H-indole PF: EXAMPLE 20 (1 H-indol-2-yl) - (4-pyridin-2-yl-piperazin-1-yl) -metanone PF: 198-200 ° C.

EXAMPLE 21 2- (4-pyridin-2-yl-piperazin-1-ylmethyl) -1 H-indole 13 C NMR (CDCl 3, 75 MHz) d 45.29, 53.03, 55.96, 77.44, 101.94, 107.29, 110.91, 113.52, 119.70, 120.28, 121.69, 128.40, 135.53, 136.37, 137.61, 148.00, 159.55. 1 H NMR (CDCl 3, 250 MHz) d 2.6, (m, 4 H), 3.6 (m, 4 H), 3.7 (s, 2 H), 6.4 (s, 1 H), 6.7 (m, 2 H), 7.1-7.6 ( m, 4H), 8.2 (m, 1 H), 8.7 (s at, 1 H). GC-MS, tR = 4468 min., M + = 292, (M-162) = 130.

EXAMPLE 22 Dihydrochloride of (2'a, 3'aß, 6'aß, -1- (4-fluoro-enyl.-4- (5'-phenyl-1 ', 2', 3 ', 3'a, 4 ', 6'a-hexahydropentalene-2'-yl) -piperazine PF: 250-253 ° C. Analysis calculated for C24H27FN2 «2HCL« O.75 H2O: C, 66.28; H, 7.07; N, 6.44. Found: C, 66.18; H, 6.76; N, 6.56.

EXAMPLE 23 Maleate of (2'a., 3'a., 5'a, 6'a?, -5'-r4- (4-fluoro-phenyl) -piperazm-l-2'-enyl-octahydro-pentalen-2 '-ol) PF: 206-207.5 ° C. Analysis calculated for C24H29FN2OO.75C4H4O4 * O.75H20: C, 67.41; H, 7.02; N, 5.82. Found: C, 67.24; H, 6.77; N, 5.68.

EXAMPLE 24 Dihydrochloride of (2'a. 3'aß. 5'a. 6'aβ) -1- (4-io-phenyl, - - (5'-phenyl-octahydropentalene-2'-yl. -piperazine MP: 255-256.5 ° C. Analysis calculated for C24H29FN2'2HCIO.25 H2O: C, 65.23; H, 7.18; N, 6.34. Found: C, 65.40; H, 7.02; N, 6.38.

EXAMPLE 25 Maleate of (2'a, 3'aß, 5'a, 6'aß, -2-fluoro-4 -, 4- (5'-hydroxy-5'-phenyl-octahydro-pentalen-2 ' -yl) -piperazin-1-n-benzonitrile PF: 207-207.5 ° C. Analysis calculated for C25H28FN3? «C4H4? 4: C, 66.78; H, 6.18; N, 8.06. Found: C, 66.64; H, 6.06; N, 8.14.

EXAMPLE 26 Maleate of (2'a. 3'aß, 5'a, 6'aß.-2-fluoro-4-, 4- (3 ', 3'a, 4', 5 ', 6', 6 ' a- hexahydroxyespiro p'sobenzofuran-1 (3H), 2 '(1?) - pentalen-1-5'-yl) -1 • piperazinyl-benzonitrile PF: 221-221.5 ° C. Analysis calculated for C26H28FN3O-C4H4? 4 * O.5 H2O: C, 66.41; H, 6.13; N, 7.74. Found: C, 66.33; H, 6.26; N, 7.61.

EXAMPLE 27 Maleate of (2'a, 3'aß, 5'a, 6'aß) -5 '.4- (2-methoxy-phenyl, -piperazin-1-ip-2'-phenyl-octahydro-pentalen- 2'-ol MP: 188-189 ° C: Analysis calculated for C25H32N2O2 »C4H4? 4: C, 68.48; H, 7.13; N, 5.51. Found: C, 68.64; H, 7.10; N, 5.81.

EXAMPLE 28 Maleate of (2'a.3'aß, 5'a.6'aß.-2- (4-fluoro-phenyl) -5'-r4- (5-pyrimidin-2-yl) -piperazin -1-p-octahydro-pentalen-2'-ol PF: 219.5-220 ° C. Analysis calculated for C22H26F2N4'C4H4O4"0.5 H2O: C, 59.41; H, 5.94; N, 10.66. Found: C, 59.76; H, 5.89; N, 10.65.

EXAMPLE 29 Maleate of (2'a. 3'aß, 5'a, 6'aß) -2-fluoro-4-.4,5 '- (4-fluoro-phenyl) -5'-hydroxy-octahydro- pentalen-2'-ip-piperazin-1-yl. -benzonitrile PF: 204-204.5 ° C. Analysis calculated for C 25 H 27 F 2 N 3 O • C 4 H 4 O 4 * H 2 O: C, 62.47; H, 5.97; N, 7.54. Found: C, 62.77; H, 5.74; N, 7.58.

EXAMPLE 30 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2 '- (4-fluorophenyl, -5' -, 4- (4-fluoro-phenol. - piperazin-1-n-octahydro-pentalen-2'-ol PF: 209-209.5 ° C. Analysis calculated for C2.H28F2N2? -C4H4? 4 ' C, 65.36; H, 6.27; N, 5.54. Found: C, 65.65; H, 6.25; N, 5.34.

EXAMPLE 31 Maleate of (2'a, 3'aß, 6'aß) -5-fluoro-2-.4- (5'-phenyl-1 ', 2', 3 ', 3'a, 4', 6 'a- hexahydro-pentalen-2'-yl) -piperazin-1-ip-pyrimidine PF: 202-203 ° C. Analysis calculated for C22H25FN4 '* C4H4? 4: C, 64. 99; H, 6.08; N, 11.66. Found: C, 64.67; H, 6.00; N, 11.79.

EXAMPLE 32 Maleate of (2'a, 3'aß, 6'aß, -2-fluoro-4-.4- (5'-phenyl-1 ', 2', 3 ', 3'a, 4'. 'a- hexahydro-pentalen-2'-yl) -piperazin-1-ip-benzonitrile PF: 172-173 ° C. Analysis calculated for C25H26FN3'C H4? 4: C, 69.17; H, 6.00; N, 8.34. Found: C, 69.06; H, 5.88; N, 8.57.

EXAMPLE 33 Maleate of (2'a, 3'aß, 5'a, 6'aß) -5-fluoro-2-r4- (5'-pheno-octahydro-pentalen-2'-yl) -piperazin- 1-in-pyrimidine PF: 211.5-212 ° C. Analysis calculated for C 22 H 27 FN 4 ** C 4 H 4 O: C, 64.72; H, 6.48; N, 11.61. Found: C, 64.67; H, 6.43; N, 11.82.

EXAMPLE 34 Maleate of (2'a, 3'aß. 5'a, 6'aß.-2-fluoro-4-.4- (5'-phenyl-octahydro-pentalen-2'-yl) -piperazin-1 -n-benzonitrile PF: 195-196 ° C. Analysis calculated for C25H28FN3 «C4H4O4: C, 68. 89; H, 6.38; N, 8.31. Found: C, 68.99; H, 6.47; N, 8.30.

EXAMPLE 35 Maleate of (2'a, 3'aß, 5'a, ß'aß.-2-fluoro-4-, 4-r5 '- (2-trifluoromethyl-phenyl-octahydro-pentalen-2'-! n-piperazin-1-yl -benzonitril PF: 192-193 ° C. Analysis calculated for C 26 H 27 F 4 N 3'C 4 H 4: C, 62.82; H, 5.45; N, 7.33. Found: C, 62.87; H, 5.22; N, 7.27.

EXAMPLE 36 Maleate of (2'a, 3'aß, 6'aß) -2 -luoro-4 .4 .5- (2-methoxy-phen-1 ', 2', 3 ', 3'a. 4'. 6'a-hexahydro-pentalen-2'-H '| -piperazin-1-ip * -benzontritrile PF: 155-156 ° C. Analysis calculated for C26H28FN3O * C4H4? 4 ** 0.25 H2O: C, 66.96; H, 6.09; N, 7.81. Found: C, 67.00; H, 6.05; N, 7.82.

EXAMPLE 37 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2-fluoro-4-.4-r5 '- (2-methoxy-enyl) -octahydro-pentalen-2' -pp¡perazin-1-il. -benzonitrile MP: 176-177 ° C. Analysis calculated for C26H3oFN3? 'C4H4? 4-0.50 H2O: C, 66.16; H, 6.48; N, 7.71. Found: C, 66.20; H, 6.31; N, 7.69.

EXAMPLE 38 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2 -luoro-4 -, 4, 5 '- (1 H -indol-3 -H.-octahydro-pentalen-2 '-n-piperazin-1-yl -benzonitrile PF: 226-227 ° C. Analysis calculated for C27H29FN4 ** C4H4? 4-C, 68.37; H, 6.11; N, 10.29. Found: C, 68.17; H, 6.24; N, 10.20.

EXAMPLE 39 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2 -luoro-4-f4-.5 ', 2-methanesulfonyl-phenyl) - octahydro-pentalen-2'- P-piperazin-1-i, -benzonitriio PF: 179-180 ° C. Analysis calculated for C26H3oFN3? 2S »C4H4? 4-0.25 H2O: C, 61.25; H, 5.91; N, 7.14. Found: C, 61.26; H, 6.32; N, 6.76.

EXAMPLE 40 Maleate of (2'a, 3'aß. 5'a. 6'aß) -2-fluoro-4 .4- (3'.3'a, 4 '. 5'.6', 6'a - hexahydroxyspiroyl, benzofuran-1 (3H), 2 '(1'H) -pentalene-1-5'-yl) -1- piperazinyl-benzonitrile PF: > 260 ° C. Analysis calculated for C 26 H 28 FN 3 O'CH 4 O 3 S: C, 63.14; H, 6.27; N, 8.18. Found: C, 63.12; H, 6.66; N, 8.00 EXAMPLE 41 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2 -fluoro-4 .4- (3, 3'.3'a, 4. 4 '. 5', 6 ' , 6'a- hexahydroxiespiro T2H-1-benzopiran-2, 2 '(1' H) -pentalene-5'-yl) -1-piperazinin-benzonitrile MP: 176-177 ° C. Analysis calculated for C27H28FN3O2'C4H4O4'0.50 H2O: C, 65.25; H, 5.82; N, 7.36. Found: C, 65.52; H, 6.06; N, 7.19.

EXAMPLE 42 Maleate of (2'a, 3'aß, 5'ß, 6'aß) -2 -luoro-4 .4- (3, 3 ', 3'a, 4, 4', 5 ', 6' , 6'a- hexahydroxyspiro f2H-1-benzopyran-2, 2 '(1'H) -pentalenl-5'-yl) -1- piperazinyl-benzonitrile PF: 179-180 ° C. Analysis calculated for C 27 H 28 FN 3 O 2'C 4 H 4 4 4: C, 66.30; H, 5.74; N, 7.48. Found: C, 66.17; H, 6.07; N, 7.34.

EXAMPLE 43 Maleate of (2'a. 3'aß, 5'a, 6'aß.-2-fluoro-4-, 4-.5 '- (2-trifluoromethoxy-phenyl, - octahydro-pentalen- 2 '-ll-piperazin-1 -yl.}. -benzom "trHo MP: 126-129 ° C. NMR DMSO d6 d 7.70 (t, J = 8.5 Hz, 1 H), 7.52 (d, J = 7.1 Hz, 1 H), 7.40-7.25 (m, 3H), 7.09 (d, J = 13.6 Hz), 6.96 (d, J = 9.0 Hz, 1H), 6.06 (s, 2H), 3.73-2.90 (ma, 10 H), 2.65-2.54 (m, partially in DMSO, 1 H), 2.46-2.18 (m, 4H) , 1.63-1.42 (m, 4H).

EXAMPLE 44 Maleate of (2'a, 3'aß, 6'aß) -2-fluoro-4-.4, 5 '- (2 -luoro-phenyl.-octahydro-pentalen-2'-ip-piperazin-1) -yl) -benzonitrile PF: 179-180.5 ° C. Analysis calculated for C 25 H 27 F 2 N 3 -C 4 H 4 4 4: C, 66.53; H, 5.97; N, 8.03. Found: C, 66.62; H, 6.24; N, 7.98.

EXAMPLE 45 Maleate of (2'a, 3'aß, 5'a, 6'aß.-2-cyano-4- { 4-.5 '- (2-fluoro-phenyl) -octah-d-pentanol -2'-il1-piperazin-1-i. -benzonitryl PF: 193-194 ° C. Analysis calculated for C26H27FN4-C4H4O4 * 0.50 H2O: C, 66.78; H, 5.98; N, 10.38. Found: C, 66.99; H, 6.05; N, 10.34.

EXAMPLE 46 Dihydrochloride of (2'a, 3'aß, 5'a, 6'aß) -2-fluoro-4-r4- (5'-pyridin-2-yl) -octahydro-pentalen-2'-yl) -piperazin-1-ill-benzonitrile PF: 203-206 ° C. Analysis calculated for C2.H27FN4-2HCI - .2O: C, 59.88; H, 6.49; N, 11.63. Found: C, 59.55; H, 6.42; N, 11.47.

EXAMPLE 47 Maleate of (2'a. 3'a., 5'a, 6'a?) -5-fluoro-2-.4-, 5 '- (2-methoxy-phenyl, -octahydro-pentalen-2'- N-piperazin-1-yl-pyrimidine PF: 183.5-184. 5 ° C. Analysis calculated for C23H29FN4O »C4H4? 4: C, 63.26; H, 6.49; N, 10.93. Found: C, 63.21; H, 6.71; N, 10.82.

EXAMPLE 48 Dymesylate of (2'a. 3'a. 5'a. 6'aß) -2-fluoro-4-.4-r 5 '- (6-fluoro-2-oxo-2,3-dihydro-benzoimidazole-1) -yl) -octahydro-pentalen-2'-ip-piperazin-1-yl > - benzonitrile PF: 219-222 ° C. Analysis calculated for C 26 H 27 FN 5 O - H C 4 O 3 S: C, 51.29; H, 5.38; N, 10.68. Found: C, 51.84; H, 5.57; N, 10.64.

EXAMPLE 49 Dimesiiate of (2'a, 3'aß, 5'a, 6'aß, -2-fluoro-4- {4-r5 '- (6-fluoro-2-methoxybenzoimidazole-1-H ) -octahydro-pentalen-2 '-ll-piperazin-1-yl) - benzonitrile PF: > 260 ° C. Analysis calculated for C27H29F2N5 * - CH4O3S «* 0.50 H2O: C, 52.56; H, 5.48; N, 10.57. Found: C, 52.64; H, 5.71; N, 10.57.

EXAMPLE 50 (2'a, 3'aß, 5'a. 6'aß) -5-fluoro-2-r4- (3 '. 3'a. 4'. 5 '. 6'. 6'a-hexahydroxiespiro - psobenzofuran-1 (3H), 2 '(1?) - pentalen-1-5' -iD-piperazin-1-pyrimidine PF: 186 ° C. NMR CDCI3 d 8.20 (s, 2H), 7.25-7.17 (m, 4H), 7.12-7.09 (m, 1 H), 5.00 (s, 2H), 3.79-3.71 (m, 4H), 2.72-2.44 (m , 7H), 2.20-2.13 (m, 2H), 2.17-1.93 (m, 2H), 1.69-1.67 (s, 2H).

EXAMPLE 51 (2'ß. 3'aß, 5'a, 6'aß) -5 -luoro-2-, 4- (3 ', 3'a, 4', 5 ', 6', 6'a- hexahidroxiespiro Usobenzofuran-1 (3H), 2 '(1'H-pentalen-5'-yl) -piperazin-1-yl-pyrimidine MP: 186-187 ° C. NMR CDCI3 d 8.18 (s, 2H), 7.26-7.10 (m, 3H), 7. 08-7.06 (m, 1H), 5.00 (s, 2H), 3.78-3.76 (sa, 4H), 2.78-2.73 (m, 2H), 2.66-2.54 (m, 5H), 2.32-2.22 (m, 4H) ), 1.74-1.69 (m, 2H), 1.38-1.29 (m, 2H).

EXAMPLE 52 Maleate of (2'a, 3'aß, 5'a, 6'aß) -1-phenyl-4 (3, 3 ', 3'a, 4, 4, 5, 6, 6. 'a- hexahydroxyspiro r2H-1-benzopyran-2, 2' (1'H) -pentalene, -5'-p-5'-yl) -piperazine PF: 200-201 ° C. Analysis calculated for C 26 H 3 o N 2 2 2'C 4 H 4 4 4: C, 69.48; H, 6.61; N, 5.40. Found: C, 69.48; H, 6.80; N, 5.44.

EXAMPLE 53 Maleate of (2'ß. 3'aß. 5'a. 6'aß) -1-phenyl-4- (3 .3 '. 3'a, 4. 4', 5 ', 6', 6 'a- hexahydroxiespiro - [_ H-1-benzopiran-2, 2' (1 'H) -pentalene-1-5'-p-5'-piperazine PF: 220-221 ° C. Analysis calculated for C 26 H 3 O N 2 2 2"C 4 H 4 4 4: C, 69.48; H, 6.61; N, 5.40. Found: C, 69.28; H, 6.84; N, 5.33.

EXAMPLE 54 Maleate of (2'a, 3'aß, 5'a. 6'aß) -3 .5 '- (4-phenyl-piperazin-1-yl) -octahydro-pentalen-2'-1-1 H-indole PF: 232-232.5 ° C. Analysis calculated for C26H3? N3 «C4H4? 4: C, 71. 83; H, 7.03; N, 8.38. Found: C, 71.57; H, 7.38; N, 8.31.

EXAMPLE 55 Dimaleate-de (2'a.3'aß.6'aß) -1-phenyl-4- (5'-phenyl-1 '. 2'. 3 '. 3'a. 4'. 6'a - hexahydro-pentalen-2'-yl) -piperazine MP: 156-157 ° C. Analysis calculated for C 26 H 3 o N 2 O 2 - * 2 C 4 H 4 4 4: C, 66.65; H, 6.29; N, 4.86. Found: C, 66.27; H, 6.57; N, 5.00.

EXAMPLE 56 Maleate of (2'a, 3'aß, 5'a, 6'aß) -1-phenyl-4- (5'-phenyl-octahydro-pentalen-2'-yl) -piperazine PF: 217-218 ° C. Analysis calculated for C 24 H 3 O N 2, C 4 H 4 4 4: C, 72.70; H, 7.41; N, 6.06. Found: C, 72.28; H, 7.46; N, 6.01.

EXAMPLE 57 Dimaleate of (2'a, 3'aß, 5'a, 6'aß) -6-fluoro-2-methyl-1-f5 '- (4-phenyl-piperazin-1-yl) -octahydro-pentalen -2'-in-1 H-benzoimidazole PF: 203-205 ° C. Analysis calculated for C26H3iFN4 * 2C4H4? 4 »0.50 H2O: C, 61.90; H, 6.11; N, 8.49. Found: C, 61.96; H, 6.01; N, 8.58.

EXAMPLE 58 Maleate of (2'a, 3'aß, 5'ß, 6'aß) -1-r5 '- (4-fluoro-phenoxy) -octahydro-pentalen-2'-p-4-phenyl-piperazine PF: 177-178 ° C. Analysis calculated for C 24 H 29 FN 2 O 2-C 4 H 4 4 4: C, 67.72; H, 6.70; N, 5.64. Found: C, 67.33; H, 6.82 N, 5.62.

EXAMPLE 59 Maleate of (2'a. 3'a. 5'ß, 6'aß, -2-.5 '- (4-enyl-piperazin-1-yl.-octahydro-pentalen-2'-n- isoindol-1,3-dione PF: 235.5-236 ° C. Analysis calculated for C 26 H 29 N 3 O 2-C 4 H 4 O 4: C, 67.78; H, 6.26; N, 7.90. Found: C, 67.71; H, 6.37; N, 7.94.

EXAMPLE 60 Maleate of (2'a, 3'aß, 5'a, 6'aß) -N- (2-f5'-r4, 5-fluoro-pyrimidin-2-yl) piperazin-1-ill-octahydro -pentalen-2'-ilMenyl) -acetamide PF: 211.5-212 ° C. Analysis calculated for C 24 H 3 o FN 5 O'C 4 H 4 4 4:, 62.33; H, 6.35; N, 12.98. Found: C, 62.07; H, 6.32; N, 12.87.

EXAMPLE 61 Maleate of (2'a, 3'aß, 5'a, 6'aß) - N- (2-l5 '.4- (4-cyano-3-fluorophenyl-piperazin-1- il] -octah¡dro-pentalen-2'-yl.}.-phenyl) -acetamide PF: 197-199 ° C. Analysis calculated for C27H3? FN4? »C4H4? 4: C, 6.18; H, 6.27; N, 9.96. Found: C, 66.06; H, 6.20; N, 9.89.

EXAMPLE 62 Masylate of (2'a.3'aß, 5'a, 6'aß) -2-fluoro-4- (4-r5 '- (2-oxo-2,3-dihydro-benzoimidazol-1-yl) ) -octahydro-pentalen-2'-8n-piperazin-1-yl) -benzonitrile PF: > 260 ° C. Analysis calculated for C26H28FN5O'CH4O3S «0.50 2O: C, 58.89; H, 6.04; N, 12.72. Found: C, 59.01; H, 6.06; N, 12.71.

EXAMPLE 63 Masylate of (2'a, 3'aß, 5'a, 6'aß) -1-f5'-r4- (5-fluoro-pyrimidin-2-yl) -piperazin-1-n-octahydro -pentalen-2 '-? l > -1,3-dihydro-benzoimidazol-2-one PF: > 260 ° C. Analysis calculated for C23H27FN60-CH4? 3S: C, 55. 58; H, 6.04; N, 16.20. Found: C, 55.48; H, 5.87; N, 16.41.

EXAMPLE 64 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2-.5'-r4- (4-cyano-3-fluoro-phenyl) -piperazin-1-ip-octahydro- pentalen-2'-yl-benzamide PF: 198.5-200 ° C. Analysis calculated for C26H29FN4? -C4H4? 4-0.50 H2O: C, 64.62; H, 6.15; N, 10.05. Found: C, 64.84; H, 6.01; N, 10.03.

EXAMPLE 65 Maleate of (2'a 3'aß, 5'a, 6'aß) -N-, 5 '- (4-enyl-piperazin-1-yl) -octahydro-pentalen-2'-ill-benzamide PF: 211-212.5 ° C. Analysis calculated for C 25 H 3 N 3 O-C 4 H 4 O 4 -O 25 H 2 O: C, 68.28; H, 7.01; N, 8.23. Found: C, 68.17; H, 6.94; N, 8.18.

EXAMPLE 66 Maleate of (2'a, 3'aß, 5'ß, 6'aß) -2-fluoro-4- (4-r 5 '- (4-fluoro-phenoxy) - octahydro-pentalen-2'- Ll-piperazin-1-yl.}. -benzontrile PF: 192-193 ° C. Analysis calculated for C25H27F2N3O2-C4H4? 4: C, 64. 55; H, 5.79; N, 7.79. Found: C, 64.50; H, 5.80; N, 7.71.

EXAMPLE 67 Maleate of (2'a. 3'a.sub.5'.sub.6'a.sub.S) -5-fluoro-2-, 4 -, 5 '- (4-fluoro-phenoxy, - octahydro-pentalen-2) '-p-piperazin-1-pyrimidine PF: 192-194 ° C. Analysis calculated for C 22 H 26 F 2 N 4 O-C 4 H 4 4 4: C, 60.46; H, 5.85; N, 10.85. Found: C, 60.30; H, 5.82; N, 10.78.

EXAMPLE 68 Maleate of (2'a. 3'aß, 5'ß, 6'aß) -2 -fluoro-4- (4-.5 '- (2-oxo-2,3-dihydrobenzoimidazol-1- il) -octahydro-pentalen-2'-yn-piperazin-1-yl.} - benzontrile MP: 170-177 ° C. NMR DMSO d6: d 10.89 (s, 1 H), 7.70 (t, J = 8.4 Hz, 1 H), 7.30-7.23 (m, 1 H), 7.11 (d, J = 13.9 Hz, 1 H), 7.04 -6.94 (m, 4H), 6.06 (s, 2H), 4.97-4.82 (m, 1 H), 3.62-2.80 (m a, 10H), 2.75-2.63 (m, 2H), 2.60-2.50 (m partially below the DMSO peak, 1 H), 2.48-2.36 (m, 2H), 1.60 (dd, Ji = 12. 4 Hz, J2 = 6.6 Hz, 2H), 1.58-1.34 (m, 2H).

EXAMPLE 69 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2 -luoro-4- (4-r5 '- (3-methoxy-phenyl) -octahydro-pentalen-2'-! n-Piperazin-1-yl) -benzonitrile PF: 169-170 ° C. Analysis calculated for C26H3oFN3O-C4H4? 4: C, 67. 27; H, 6.40; N, 7.85. Found: C, 67.18; H, 6.52; N, 7.87.

EXAMPLE 70 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2-fluoro-4-.4-.5 '- (4-methoxy-phenyl-octahydro-pentalen-2' - ill-piperaz? n-1-N) -benzonitrile PF: 186-186.5 ° C. Analysis calculated for C26H3oFN3O-C4H4? 4-0.25 H2O: C, 66.71; H, 6.44; N, 7.78. Found: C, 66.70; H, 6.60; N, 7.60.

EXAMPLE 71 Maleate of (2'a, 3'aß, 5'a, 6'aß.-2-fluoro-4-.4-r5'-m-tom-octahydro-pentalen-2'-ill-piperazin-1 -in-benzonitrile PF: 198-198.5 ° C. Analysis calculated for C26H3oFN3-C4H4? 4: C, 69. 35; H, 6.60; N, 8.09. Found: C, 69.48; H, 6.74; N, 8.14.

EXAMPLE 72 Maleate of (2'a. 3'a. 5'a. 6'aß) -2-fluoro-4-r4- (5'-p-tolyl-octahydro-pentalen-2'-ill-piperazin-1) -ill-benzonitrile PF: 194-195 ° C. NMR DMSO d6: d 7.70 (t, J = 8.5 Hz, 1 H), 7.16-7.09 (m, 5H), 6.96 (d, J = 8.7 Hz, 1 H), 6.06 (s, 2H), 3.75-2.85 (m, 11 H), 2.55-2.43 (m partially below the peak of DMSO, 1H), 2.40-2.23 (m, with singlet at 2.26, 7H, total), 1.63-1.32 (m, 4H).

EXAMPLE 73 Maleate of (2'ß. 3'aß. 5'ß. 6'aß) -1-.5 '- (4-fluorophenoxy-octahydro-pentalen-2'-.p-4-phenyl-piperazine PF: 174-175.5 ° C. Analysis calculated for C 24 H 29 FN 2 O-C 4 H 4 4 4: C, 67.72; H, 6.70; N, 5.64. Found: C, 67.82; H, 6.83; N, 5.59.

EXAMPLE 74 Maleate of (2'a, 3'aß, 5'a, 6'aß) -2 -luoro-4-, 4- (5'-o-tolyl-octahydro-pentalen-2'-yl, -piperazin -1 -ill-benzonitrile PF: 198-199 ° C. Analysis calculated for C 26 H 3 or FN 3 2 2-C 4 H 4 4 4: C, 69.35; H, 6.60; N, 8.09. Found: C, 69.13; H, 6.69; N, 8.12.

EXAMPLE 75 Dimaleate of (2'a, 3'aß, 5'a, 6'aß) -1-phenyl-4-r5 '- (3-pyrrolidin-1-ylmethyl-phenin-octahydro-pentalen-2'-il1 -piperazine MP: 163.5-164 ° C. Analysis calculated for C29H39N3 -2C4H4? 4: C, 67. fifteen; H, 7.16; N, 6.35. Found: C, 66.81; H, 7.22; N, 6.27.

EXAMPLE 76 Maleate of (2'a, 3'aß, 5'a, 6'aß) -5-fluoro-2-r4- (3 '. 3'a. 4'. 5 '. 6', 6'a -hexahydro-3'a, 6'a-dimethylspiropsobenzofuran-1 (3H) 2 '(l'H) -pentalenl-5'-yl) -1-piperazinin-pyrimidine PF: 224.5-225 ° C. Analysis calculated for C25H31FN4O • C4H4O4O.25 H2O: C, 64.13; H, 6.59; N, 10.32. Found: C, 64.25; H, 6.68; N, 10.14.

EXAMPLE 77 Maleate of (2'ß. 3'aß. 5'a. 6'aß) -5-fluoro-2, 4- (3 ', 3'a, 4', 5 ', 6', 6'a -hexahydro-3'a. 6'a-dimethyl-spiro-isobenzofuran-1 (3H., 2 '(1'H) -pentalene-5'-yl) -1- piperazinin-pyrimidine PF: 222-223 ° C. NMR DMSO d6: d 8.58 (s, 2H), 7.34-7.30 (m, 1H), 7.28-7.25 (m, 3H), 6.04 (s, 2H), 4.94 (s, 2H), 3.65-2.75 (ma, 9H), 2.20-2.12 (m, 2H), 1.94 (AB quartet, ?? = 37.8 Hz, J = 13.2 Hz, 4H), 1.54 (ta, J 11.7 Hz, 2H), 1.21 (s, 6H).

EXAMPLE 78 Maleate of (2'a, 3'aß, 5'ß, 6'aß) -4-.4-r5 '- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) - octahydro-pentalen-1-2'-1-piperazin-1-yl > -2-fluoro-benzonitrile PF: 224.5-225 ° C. Analysis calculated for C27H27FN? 2-C4H4? 4: C, 64.80; H, 5.44; N, 9.75. Found: C, 64.85; H, 5.56; N, 9.74.

EXAMPLE 79 Maleate of (2'a, 3'aß, 5'ß, 6'aß) -2-.5 '.4- (5-fluoro-pyrimidin-2-yl-p-piperazin) 1-p-octahydro-pentalen-2'-yl.}. -isoindole-1,3-dione PF: 241.5-242 ° C. Analysis calculated for C24H26FN5O2-C4H4? 4: C, 60.97; H, 5.48; N, 12.70. Found: C, 60.66; H, 5.55; N, 12.44.

EXAMPLE 80 Maleate of (2'a. 3'aß, 5'a, 6'aß) -2-fluoro-4-r4- (3, 3 ', 3'a, 4, 4', 5 ', 6' , 6'a-hexahydrospiro .2H-6-fluoro-1-benzopyran-2, 2 '(1? .- pentalen, -5'-yl-5' -yl-1-piperazinyl-benzonitrile PF: 219-220 ° C. Analysis calculated for C 24 H 26 F 2 N 4 2 2-C 4 H 4 4 4-0.50 H 2 O: C, 59.46; H, 5.55; N, 9.90. Found: C, 59.86; H, 5.70; N, 9.40.

EXAMPLE 81 Maleate of (2'ß, 3'aß, 5'a, 6'aß) -2-fluoro-4-r4- (3,3 ', 3'a, 4,4', 5 ', 6' , 6'a- hexahydrospiro r2H-6-fluoro-1-benzopyran-2, 2 '- (1?) -pentalene-5'-p-5'-yl) -1-piperazine-benzonitrile PF: 216.5-217 ° C. Analysis calculated for C24H26F2N4? 2-C4H4? 4: C, 60.43; H, 5.43; N, 10.07. Found: C, 60.39; H, 5.47; N, 9.90.

EXAMPLE 82 Maleate of (2'a, 3'aß, 5'a, 6'aß, -5-fluoro-2-.4-r5'-ototyl-octahydro-pentalen-2'-yl) -piperazin-1- in-pyrimidine PF: 204-205 ° C. Analysis calculated for C23H29FN4-C4H4? 4: C, 65.31; H, 6.70; N, 11.28. Found: C, 65.38; H, 6.77; N, 11.32.

EXAMPLE 83 Maleate of (2'ß. 3'aß. 5'a. 6, aß, -1-.5Y4- (4-fluoro-phenyl) -piperazin-1-p-octahydro-pentalen-2 ' -yl> -1,3-dihydro-benzoimidazol-2-one PF: 217-218 ° C. Analysis calculated for C25H29FN4? -C4H4? 4: C, 64. 91; H, 6.20; N, 10.44. Found: C, 64.57; H, 6.28; N, 10.18.

EXAMPLE 84 Maleate of (2'ß, 3'aß, 5'a, 6'aß) -2-.5 ', 4-phenyl-piperazin-1-yl) -octahydro-pentalen-2'-iloxp -1H-benzoimidazole MP: 161-162 ° C. Analysis calculated for C25H3oN4? -C4H4? 4: C, 67.16; H, 6.61; N, 10.80. Found: C, 67.05; H, 6.66; N, 10.59.

EXAMPLE 85 Maleate of (2'a, 3'aß, 5'a, 6'aß.-5-chloro-2- (4-.5 '- (2-methoxy-phenyl) -octahydro-pentalen-2' -ip-piperazin-1-pyrimidine PF: 199.5-200 ° C. Analysis calculated for C23H29CIN4? 2-C4H4? 4: C, 61.30; H, 6.29; N, 10.59. Found: C, 61.05; H, 6.31; N, 10.83.

EXAMPLE 86 Maleate of (2'a. 3'aß, 5'a, 6'aB, -5-chloro-2-.4-r5'-o-tolH-octahydro-pentalen-2'-yl) -piperazin- 1-pyrimidine PF: 200-200.5 ° C. Analysis calculated for C23H29CIN4-C4H4? 4: C, 63. twenty-one; H, 6.48; N, 10.92. Found: C, 62.97; H, 6.33; N, 11.29.

EXAMPLE 87 Maleate of (2'ß. 3'aß. 5'a. 6'aß) -2-, 5'-r4- (3,4-difluoro-phenyl) -piperazin-1-n-octahydro-pentalen-2 '-il > -isoindole-1,3-dione PF: 221.5-222 ° C. Analysis calculated for C 26 H 27 F 2 N 3 2 2-C 4 H 4 4 4: C, 63.48; H, 5.51; N, 7.46. Found: C, 63.28; H, 5.51; N, 7.64.

EXAMPLE 88 Maleate of (2'ß, 3'aß, 5'a, 6'aß) -2 .5 '.4- (4-fluorophenyl, -piperazin-1-yl-octahydro-pentalen-2'- il > -isoindol-1,3-dione PF: 209-210 ° C. Analysis calculated for C26H28FN3O2-C4H4O4-0.50 H2O: C, 64.51; H, 5.95; N, 7.52. Found: C, 64.47; H, 5.91; N, 7.66.

EXAMPLE 89 Maleate of (2'ß, 3'aß, 5'a, 6'aß) -1-. { 5'-r4- (3,4-Dffluoro-phenyl-piperazin-1-p-octahydro-pentalen-2'-yl) -1,3-dihydro-benzoimidazol-2-one PF: 201-202 ° C. Analysis calculated for C25H28F2N4O-C4H4O4-0.50 H2O: C, 61.80; H, 5.90; N, 9.94. Found: C, 62.10; H, 5.80; N, 9.56.

Claims (21)

1. NOVELTY OF THE INVENTION CLAIMS 1. - A compound of formula or the pharmaceutically acceptable salt thereof, wherein the dotted line represents an optional double bond; a is 0 or 1, wherein when a is O, X can form an optional double bond with the carbon adjacent to V; V is CHR10, wherein R10 is hydrogen or alkyl (C -? - C6); T is nitrogen or CH; X is nitrogen or CR11, wherein R11 is hydrogen, alkyl (C? -C6), alkoxy (CrC6), hydroxy or cyano; Y and Z are each independently nitrogen or CR12, wherein R12 is hydrogen, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C? -C6) alkoxy or alkyl (Cr6); R1 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or (C -? - C6) alkyl; R2, R6, R7, R8 and R9 are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, (C? -C6) alkoxy and (C-i-C6) alkyl; R3 and R4 are each independently hydrogen or alkyl (CI-CT); and R 5 is hydrogen, (C 1 -C 2) alkoxy, trifluoromethyl, cyano, (C 6) alkyl, or e "n e? l q" .u, e? r R > 13 is amino, alkyl (CrC6) amino, (alkyl (CrC6)) 2 amino, alkyl (C? -C6), aryl (C6-C? O); or when a is 1, R1 and R10 can be linked with the carbons to which they are attached to form a compound of formula wherein the dashed lines represent optional links; T, X, Y, Z, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined above; b is O or 1; and A and B are each independently CH, CH2, oxygen, sulfur, NH or nitrogen; with the proviso that when X is nitrogen, the optional double bond between X and V does not exist; with the proviso that when b is 0, the optional double bond between A and B does not exist; and with the proviso that when b is 1, A and B can not be any of them oxygen or sulfur.
2. 2. A compound according to claim 1, wherein X is nitrogen.
3. 3. A compound according to claim 1, wherein Y and Z are each CR12, wherein R12 is nitrogen or fluoro.
4. 4. A compound according to claim 1, wherein R2 is hydrogen, fluoro or chloro.
5. 5. A compound according to claim 1 wherein R3, R4 and R5 are hydrogen. 6. - A compound according to claim 1, wherein R is fluoro or chloro. 7. A compound according to claim 1, wherein R9 is fluoro, chloro, bromo or alkoxy. 8. A compound according to claim 1, wherein X is nitrogen; Y and Z are each CR12, wherein R12 is hydrogen or fluoro; R2 is hydrogen, fluoro or chloro; R3, R4 and R5 are hydrogen; R7 is fluoro or chloro; and R7 is fluoro, chloro, bromo or alkoxy. 9. A compound according to claim 1, wherein said compound is selected from the group consisting of: 2- [4- (3-trifluoromethyl-phenyl) -piperazin-1-methylmethyl] -1H-indole; 5-fluoro-2- [4- (3-trifluoromethyl-phenyl) -piperazin-1-ylmethyl] -1 H-indole; 5-fluoro-2- [4- (4-fluoro-phenyl) -piperazin-1-ylmethyl] -1H-indole; 5-fluoro-2- (4-pyridin-2-yl-piperazin-1-ylmethyl] -1H-indole; 2- [4- (6-cyoro-pyridazin-3-yl) -piperazin-1-yl- methyl] -5-fluoro-1 H-indole; 5-fluoro-2- (4- [5'-fluoro] pyridin-2-yl-piperazin-1-ylmethyl) -1H-indole; - (4-pyridin-2-yl-piperazin-1-ylmethyl) -1 H-azaindole; 5-fluoro-2- (4-pyridin-2-yl-piperazin-1-ylmethyl) -1 H -azaindole; and 2- [4- (4-fluoro-phenyl) -piperazin-1-ylmethyl] -1H-azaindole 10.- The use of a selective compound of the dopamine D4 receptor according to claim 1, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disorder of the dopamine system in a mammal 11. The use according to claim 10, wherein the disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical substance abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders, eye disorders and sleep disorders 12. The use of a selective compound of the dopamine D4 receptor according to claim 1, or a pharmaceutically acceptable salt thereof, together with one or more receptor agonists D1, D2, D3 or D5 of dopamine for the preparation of a medicament for treating a disorder of the dopamine system in a mammal. 13. The use according to claim 12, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical substance abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders. , eye disorders and sleep disorders. 14. The use according to claim 11, wherein the psychotic disorders include affective psychosis, schizophrenia and schizoaffective disorders. 15. The use according to claim 11, wherein the movement disorders include the extrapyramidal side effects of neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette syndrome, Parkinson's disease. or Huntington's disease. 16. The use according to claim 11, wherein the gastrointestinal disorders include gastric acid secretion or emesis. 17. The use according to claim 11, wherein the vascular and cardiovascular disorders include congestive heart failure and hypertension. 18. A pharmaceutical composition for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a selective compound of the dopamine D4 receptor according to claim 1, or a pharmaceutically acceptable salt of it, which is effective to treat such disorder. 19. A pharmaceutical composition according to claim 18, wherein disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical substance abuse, chemical dependencies, substance abuse, vascular disorders and cardiovascular diseases, eye disorders and sleep disorders. 20. A pharmaceutical composition for treating a disorder of the dopamine system in a mammal, comprising administering to said mammal an amount of a selective compound of the dopamine D4 receptor according to claim 1, or a pharmaceutically acceptable salt thereof, together with one or more D1, D2, D3 or D5 receptor agonists of dopamine, which is effective in treating said disorder. 21. A pharmaceutical composition according to claim 20, wherein the disorders of the dopamine system include psychotic disorders, movement disorders, gastrointestinal disorders, chemical substance abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders, eye disorders and sleep disorders.